S-337395

Phase 2

Shionogi (SGIOY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

SGIOYPhase 2$14.8B

S-337395 Phase 2 Est. Readout

S-337395• Respiratory Syncytial Virus Infections192

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Respiratory Syncytial Virus Infections

View Full Landscape

Drug Information

Target Indication

Respiratory Syncytial Virus Infections

Clinical Trial

NCT07214571

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SGIOY

Shionogi

Healthcare•North America•NASDAQ

Related Pipeline

Ospemifene 60Mg Oral TabletPhase 3

Atrophy

Oral Glycopyrrolate LiquidPhase 3

Cerebral Palsy

Ospemifene (Dose 1)Phase 3

Atrophy

Ospemifene 30 mgPhase 3

Atrophy

MeropenemPhase 3

Healthcare-associated Pneumonia (HCAP)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts